Comparing the current results to its competitors, Os Therapies Incorporated reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 12.23 %, recorded in the same quarter.
Os Therapies Incorporated, slower than the average decrease reported by the company's competitors of -6.3 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -6.3 %
Os Therapies Incorporated's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industries, which are characterized by rapid technological advancement and evolving regulatory requirements. It faces competition from large pharmaceutical companies, biotechnology firms, academic institutions, government agencies, and other research organizations developing or commercializing therapies for cancer and rare diseases, including Osteosarcoma. While the company is not aware of any adjuvant therapy for pediatric Osteosarcoma more advanced than its OST-HER2 product, several organizations are developing competing therapies. Notable competitors include AstraZeneca, Y-mAbs Therapeutics, and academic institutions such as MD Anderson Cancer Center. Key competitive factors include successful product development, clinical trial safety and efficacy, regulatory approvals, intellectual property protection, manufacturing capabilities, reimbursement, and commercialization success.
Publicly Traded Peers of Os Therapies Incorporated
Addex Therapeutics Ltd Share Performance
-9.46%
Over The Past 5 Days
Addex Therapeutics Ltd
Profile
Addex Therapeutics Ltd operates under a business model focused on the discovery and development of novel, orally available small molecule drugs that target specific receptors in the central nervous system. The company combines its expertise in medicinal chemistry and drug development to advance its pipeline of potential therapeutics for neurological disorders.
Galapagos Nv's business model is centered around the development and commercialization of innovative medicines. They leverage their expertise in drug discovery and development to collaborate with partners in the healthcare industry, focusing on the advancement of novel therapies to address unmet medical needs.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Biovie Inc is a biotechnology company that aims to develop advanced therapeutic solutions for various diseases. They have a unique business model that focuses on research and development of innovative drugs, strategic partnerships and collaborations with other organizations, along with potential commercialization of their products to generate revenue. Their goal is to create groundbreaking medical treatments that improve the quality of life for patients.
Sources:
Os Therapies Incorporated’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Os Therapies Incorporated versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
